Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunosuppression with ruxolitinib and abatacept in immune checkpoint inhibitor-associated myocarditis: a temporal cohort comparison.

Revista espanola de cardiologia (English ed.)·2026

Same author

Clinical value of gated SPECT-derived left ventricular strain and reserve: derivation of quantitative cutoffs.

European journal of nuclear medicine and molecular imaging·2026

Same author

Thrombus and Aortic Wall <sup>18</sup>F-FDG Positron Emission Tomography Uptake in Abdominal Aortic Aneurysms.

Arteriosclerosis, thrombosis, and vascular biology·2026

Same author

Is the Invasive Strategy Beneficial in Frail Older Patients With NSTEMI?

JAMA network open·2026

Same author

Mortality Benefit of Microaxial Flow Pump Use in Infarct-Related Cardiogenic Shock: a Bayesian Reanalysis of the DanGer Shock Trial.

CJC open·2026

Same author

Electrocardiographic imaging-aided stereotactic radioablation as an alternative therapy for refractory premature ventricular complexes.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

[Composite endpoints in clinical trials].

Ignacio Ferreira-González¹, Pablo Alonso-Coello, Ivan Solà

¹CIBER de Epidemiología y Salud Pública, Unidad de Epidemiología, Servicio de Cardiología, Hospital Vall d'Hebron, Barcelona, España.

Revista Espanola De Cardiologia

|March 26, 2008

Summary

This summary is machine-generated.

Composite endpoints in clinical trials can reduce sample size but risk misinterpretation due to component heterogeneity. This review discusses their use and interpretation, highlighting misleading composite endpoints in cardiovascular research.

More Related Videos

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Experiment Videos

Last Updated: Jul 6, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Area of Science:

Clinical Trials
Biostatistics
Cardiovascular Medicine

Background:

Composite endpoints are frequently utilized in clinical trials, particularly in cardiovascular research.
Advantages include reduced sample size, net intervention effect assessment, and bias mitigation with competing risks.
However, heterogeneity in component importance, event frequency, or treatment effect magnitude can lead to misinterpretation.

Purpose of the Study:

To provide a conceptual discussion on the rationale and interpretation of composite endpoints.
To offer a user-friendly guide for interpreting clinical trial results based on composite endpoints.
To present an empirical study examining the use of misleading composite endpoints in cardiovascular trials.

Main Methods:

Conceptual review of composite endpoint methodology.
Development of a practical guide for result interpretation.
Empirical analysis of cardiovascular clinical trials using composite endpoints.

Main Results:

Identified potential for misinterpretation due to heterogeneity within composite endpoints.
Demonstrated the utility of a structured approach for interpreting composite endpoint data.
Provided evidence of misleading composite endpoints being used in cardiovascular clinical trials.

Conclusions:

Composite endpoints offer benefits but require careful interpretation to avoid misleading conclusions.
Understanding component-specific effects is crucial for accurate assessment of interventions.
Further research and standardized reporting are needed to ensure clarity in composite endpoint utilization.